RNA Analysis Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services, Instruments), By Technology (qPCR, Microarray, Sequencing), By Application, By End Use, By Region, And Segment Forecasts

RNA Analysis Market Summary

The global RNA analysis market size was estimated at USD 8.62 billion in 2024 and is projected to reach USD 23.65 billion by 2033, growing at a CAGR of 12.55% from 2025 to 2033. This growth is driven by the rising demand for transcriptomic studies in precision medicine, advancements in next-generation sequencing (NGS) technologies, and increasing applications of RNA biomarkers in disease diagnostics and drug discovery.

Advances in sequencing technologies

Rapid technological advancements in RNA sequencing have been a major catalyst for the growth of the RNA analysis market. Next-generation sequencing (NGS) platforms have revolutionized transcriptomics by enabling high-throughput, accurate, and cost-effective analysis of RNA molecules across multiple samples simultaneously. These technologies allow researchers to explore gene expression patterns in unprecedented detail, uncover novel RNA variants, and gain insights into complex cellular processes.

Moreover, continuous improvements in sequencing speed, accuracy, and data output have made RNA analysis more accessible and scalable for pharmaceutical, biotechnology, and academic research applications. High-throughput transcriptomics platforms currently facilitate large-scale studies that were earlier time- and cost-prohibitive, thus allowing a more in-depth consideration of disease mechanisms and biomarker discovery. Hence, adopting advanced sequencing technologies drives sustained demand for RNA analysis solutions across various research and clinical applications, placing the market for substantial growth.

Drug development and vaccine research

The research activities of the pharmaceutical industry and biotechnological sectors are increasingly relying upon RNA analysis, and hence, the market is witnessing substantial growth. RNA profiling has enabled researchers to understand cellular processes more deeply, identify novel drug action targets, and study disease pathways with high precision. This becomes extremely important in areas such as oncology, infectious diseases, and rare genetic disorders, where such knowledge of gene expression patterns could significantly speed up bringing the most appropriate therapeutics into existence.

RNA therapeutics, including mRNA vaccines and RNAi therapeutics, generate increased demand. The commercial success of mRNA vaccines during the past viral pandemics paved the way for the RNA platforms to garner increased interest from commercial and government bodies. High-throughput RNA sequencing, in combination with state-of-the-art bioinformatics tools, is increasingly utilized to expedite vaccine development, monitor immune response, and identify possible safety concerns. Pharmaceutical companies and biotechnology firms, thus, working on RNA analysis, are improving their capabilities and promoting continuous growth while creating long-term opportunities in the global RNA analysis market.

Market Concentration & Characteristics

The RNA analysis industry is characterized by a high degree of innovation, driven by rapid advancements in sequencing technologies, bioinformatics tools, and RNA-based therapeutics. More accurate, high-throughput, and economical gene expression analysis is made possible by ongoing advancements in single-cell and next-generation RNA sequencing systems. Faster biomarker discovery and applications in personalized medicine are made possible by AI and machine learning advancements, which also improve the interpretation of complex transcriptome data. Creating revolutionary RNA-based therapeutics, such as mRNA vaccines and RNA interference (RNAi) treatments, also leads to large investments in state-of-the-art analytical tools, which support the market's inventive environment and promote steady growth in both the clinical and research sectors.

The RNA analysis industry has witnessed a moderate to high mergers and acquisitions, indicative of businesses' strategic attempts to broaden their product lines, technological prowess, and worldwide presence. Major firms actively pursue collaborations and acquisitions to access cutting-edge sequencing technology, bioinformatics tools, and specialist RNA analysis solutions. For instance, in August 2023, Danaher, a U.S.-based medical tool supplier, acquired British biotech firm Abcam for USD 5.7 billion. Abcam became a standalone entity within Danaher's Life Sciences division. Abcam emerged as a separate business inside the Life Sciences division of Danaher.

Regulatory frameworks are crucial in shaping the RNA analysis industry, influencing research and clinical applications. Stringent guidelines governing the use of genetic and transcriptomic data, clinical trials, and RNA-based therapeutics ensure the safety, efficacy, and ethical use of RNA technologies. For those involved in developing and commercializing RNA diagnostics and therapeutics, it is critical to comply with the requirements of various national regulatory agencies (for example, the FDA, EMA, and other regional regulatory authorities). Although sometimes seen as a burden and a delay in getting products to market, regulation ultimately supports innovation, as firms move forward with the required and adopt even higher standards for quality, must conduct extensive verification testing, and report transparently. Overall, regulation increases market confidence, protects end users, and supports developing, marketing, and disseminating safe and efficacious RNA products.

Continuous product expansion is a significant growth driver in the RNA analysis industry, mainly because companies are working towards addressing the broad and changing needs of research and clinical uses. Leading companies are developing and selling new RNA sequencing kits, reagents, consumables, and integrated analysis platforms with improved sensitivity, throughput, and accuracy.

Geographic expansion is a key growth driver in the RNA analysis industry, as companies increasingly seek to establish a presence in emerging markets alongside established regions like North America and Europe. Expanding into Asia-Pacific, Latin America, and the Middle East allows market players to tap into growing research initiatives, rising healthcare infrastructure investments, and increasing adoption of advanced genomic technologies. By broadening their geographic footprint, companies can capture new revenue streams, strengthen brand recognition, and respond more effectively to regional demands, driving sustained market growth.

Product Insights

The kits & reagents products segment dominated the global market in 2024, accounting for 59.18% of the overall revenue. Rising requirements for high-quality reagents and kits, coupled with the repeated usage of reagents and media in transcriptome studies, drive the growth of this segment. High-quality reagents and kits deliver unmatched efficiency and strong performance, ensuring reliable and reproducible sequencing outcomes at a minimal cost.

The services segment is expected to grow at the fastest CAGR from 2025 to 2033. Growing R&D activities in the pharmaceutical sector and increasing government investments in life science research are expected to raise the demand for RNA analysis services. Several companies, such as Eurofins Scientific, Genewiz, and QIAGEN, offer various RNA analysis services, including mRNA sequencing, transcriptome profiling, and end-to-end solutions such as RNA sample preparation, library construction, sequencing, and data analysis. Availability of various services is expected to boost the market in the coming years.

Technology Insights

The real-time-PCR (qPCR) technology segment dominated the market in 2024 and accounted for the largest share of 43.34% of the global revenue. The high share was attributed to the wide usage of PCR for COVID-19 diagnostics across the globe. The qPCR technology is highly sensitive & quantitative, and one of the most suitable methods for interrogating a comparatively small number of transcripts in a broad set of samples. PCR offers relatively high-sensitivity detection of SARS-CoV-2, evaluation of viral RNA in various clinical samples, detection of SARS-CoV-2 mutations, and evaluation of anti-SARS-CoV-2 drugs.

The sequencing segment is anticipated to witness the fastest CAGR throughout the forecast period, owing to advancements in next-generation and SMRT sequencing technology. The presence of several companies providing single-cell RNA sequencing services and the advent of bioinformatics algorithms are also driving the market. Furthermore, increasing scientific awareness and decreasing costs of sequencing technologies are expected to fuel the segment over the forecast period.

Application Insights

The infectious diseases and pathogenesis application segment dominated the market with a share of 17.90% in 2024. The identification of susceptible cells is crucial for understanding the pathogenic mechanism. Hence, there is increasing adoption of scRNA-sequencing to provide information about cell types susceptible to infection. Next-generation sequencing transforms the approach to infectious diseases, pathogenesis, and treating individuals. Various methodologies have been developed for measuring gene expression and biomarkers to make their translation into clinical practice more feasible.

The epigenetics segment is expected to grow significantly from 2025 to 2033, as the pharmaceutical importance of understanding epigenetics for studying disease prognosis and epidemiology is gradually increasing. In addition, molecular dynamics will also become a versatile tool to complement experimental investigations of RNA structural dynamics to provide opportunities for expanding the field and maximizing gains from the molecular dynamics simulations, without any further methodological advances. As epigenetic modifications such as DNA methylation and histone modifications can alter the binding of transcription factors and other regulatory proteins, epigenetic analyses for understanding gene expression are expected to be highly demanded soon.

End Use Insights

The government institutes & academic centers segment held the highest revenue share of 32.11% in 2024. The rising adoption rate of high-throughput technologies for the effective process of RNA analysis by government institutes and academic centers drives the segment growth. Increasing applications of transcriptomics technologies in drug discovery propel the demand in the pharmaceutical and biotechnological industries. Similarly, drug discovery research contributes to the market, followed by clinical diagnostics. For instance, in April 2021, researchers developed TORNADO-seq, an RNA sequencing-based drug discovery platform to monitor the expression of the large gene for a detailed study of organoid cellular phenotypes.

The Contract Research Organizations (CROs) segment is expected to grow at the fastest CAGR over the forecast period. Strategic activities by key market players support the segment growth. For instance, in Jan 2022, 10x Genomics announced the expansion of its 10x Certified Service Provider Network to incorporate three leading CROs. The CROs will partner with 10x Genomics to support leading biopharmaceutical companies seeking the advantage of 10x Genomics’ single-cell and spatial technologies to accelerate drug development and power novel therapeutic findings. The three CROs chosen for the 10x Genomics program are Azenta Life Sciences, Q2 Solutions, and CellCarta.

Regional Insights

North America dominated the RNA analysis industry in 2024, accounting for a share of 43.49%, due to established pharmaceutical and biotechnology companies, strong research infrastructure, and a large investment in genomic and transcriptomic analysis. The region benefits from widespread adoption of next-generation sequencing (NGS) technologies, a high concentration of academic and clinical research institutions, and strong government and private funding initiatives supporting RNA-based studies and therapeutics.

U.S. RNA Analysis Market Trends

The U.S. dominates the global RNA analysis market due to its advanced research infrastructure, high biotechnology and pharmaceutical companies concentration, and significant public and private funding for genomic studies. Widespread adoption of next-generation sequencing (NGS) and single-cell RNA sequencing technologies, combined with the success of RNA-based therapeutics, continues to strengthen the U.S. market.

Europe RNA Analysis Market Trends

Europe held a significant share in the RNA analysis market, driven by robust research activities, favorable regulatory support, and increasing collaborations between academic institutions and biotechnology firms. Countries such as Germany, the United Kingdom, and France stand out as key players in the region due to their advanced research infrastructure, strong governmental initiatives to support precision medicine, and high uptake of next-generation sequencing (NGS) technologies. The presence of leading pharmaceutical and biotech companies and participation in clinical trials and RNA-based therapeutic development further support the market.

The UK RNA analysis market benefits from advanced research infrastructure, government-backed genomic projects, and collaborations between academic institutions and biotechnology firms. The country’s focus on clinical trials, RNA therapeutics, and personalized medicine supports steady growth in RNA analysis adoption.

The Germany RNA analysis market remains a primary European market for RNA analysis, backed by strong research academic programs, established biotechnology and pharmaceutical industries, and government-supported initiatives for precision medicine. Investing in translational research and clinical applications of RNA technologies in Germany continues to create demand for a reliable sequencing platform or an appropriate bioinformatics tool.

Asia Pacific RNA Analysis Market Trends

The Asia Pacific region is expected to grow at the fastest CAGR of 13.41% from 2025 to 2033. The Japanese government and non-government organizations highly support the growth of biotechnology research in the country and provide funds for research in medicine and life sciences. This encourages researchers to explore the transcriptomics space actively. Furthermore, increasing focus on APAC countries, owing to the low-cost manufacturing service, is expected to provide growth opportunities for the manufacturers. In addition, strategic activities, such as partnerships, will further augment the growth of this region. For instance, in January 2020, Genetron Holdings Ltd. entered into a strategic partnership agreement with Thermo Fisher Scientific to expand its precision cancer monitoring and diagnosis in China’s public hospitals.

The China RNA analysis market is emerging as one of the fastest-growing RNA analysis markets due to increasing research investments, expanding healthcare infrastructure, and rising adoption of next-generation sequencing technologies. Government initiatives promoting genomics and precision medicine and collaborations with global biotech companies are further boosting market demand.

The Japan RNA analysis market is a leading market in Asia, driven by significant investments in biotechnology, active government support for genomic research, and adoption of advanced RNA sequencing technologies. Pharmaceutical research and the development of RNA-based therapeutics are key growth factors in the country.

Middle East & Africa RNA Analysis Market Trends

The MEA region is gradually emerging as a growth market for RNA analysis, supported by increasing government investment in healthcare research and rising awareness of personalized medicine. Countries like Kuwait, the UAE, and Saudi Arabia are expanding their research infrastructure and forming collaborations with international biotech and pharmaceutical firms. Although adoption rates are lower compared to North America and Europe, growing clinical research initiatives, improving laboratory facilities, and an increasing focus on rare genetic disorders drive steady market growth in this region.

Kuwait is gradually entering the RNA analysis market, supported by government funding in healthcare research and partnerships with international biotechnology firms. The country is focused on improving laboratory infrastructure and expanding clinical research initiatives, contributing to moderate market growth in the MEA region.

Key RNA Analysis Company Insights

The RNA analysis industry features some established competitors through broad portfolios, partnerships, and ongoing investments in research and development. Key sector players such as Agilent Technologies, F. Hoffmann-La Roche, Illumina, QIAGEN, and Thermo Fisher Scientific hold substantial market share in RNA analysis markets by offering advanced RNA sequencing systems, sample preparation or kits, high-throughput analysis platforms, and the ability to enter the RNA analysis markets with bioinformatics and distribution networks that lead to global reach.

By offering cutting-edge solutions and customized RNA analysis services that meet the changing needs of academic institutions, pharmaceutical companies, and clinical research organizations, businesses like Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Pacific Bioscience of California, Affymetrix, Danaher, and Promega are growing their footprint. These services include RNA-based biomarker discovery platforms, transcriptomic profiling, and single-cell RNA sequencing.

Prominent companies keep strengthening their position in the market by fusing state-of-the-art technology with extensive service offerings and calculated expansion plans. These companies have cemented their market leadership by meeting the growing need for accurate RNA profiling in precision medicine, drug discovery, infectious disease research, and RNA-based therapeutics. As the adoption of RNA sequencing technologies picks up speed, the competitive landscape is being shaped more and more by dedication to innovation, accessibility, and data accuracy. These factors are essential for the advancement of clinical and research applications.

The market for RNA analysis is dynamically interacting with new developments and well-established knowledge. Competition is getting more intense due to strategic alliances, mergers and acquisitions, and advancements in data interpretation and sequencing efficiency. In this quickly changing industry, businesses that successfully combine technological innovation with customer-focused solutions will be well-positioned to create long-term value and support the expansion of transcriptomics, personalized medicine, and RNA-based therapeutic development.

Recent Developments

• In August 2025, Skyhawk Therapeutics entered a strategic collaboration with Merck KGaA, Darmstadt, Germany, to discover RNA-targeting small molecules for neurological disorders, with Skyhawk leading discovery and preclinical development.

• In February 2025, Bio-Rad Laboratories offered to acquire Stilla Technologies, France and U.S.-based developer of next-generation digital PCR solutions, aiming to complement its portfolio and accelerate digital PCR innovation globally.

RNA Analysis Market Report Scope

Global RNA Analysis Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global RNA analysis market on the basis of product, technology, application, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

  • Kits & Reagents

    • miRNA & siRNA

    • Reverse Transcriptases & RT-PCR

    • RNA Extraction & Purification

    • RNA Interference

    • Others

  • Services

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Real Time-PCR (qPCR)

  • Microarray

  • Sequencing

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Construction of RNA expression atlas

  • Epigenetics

  • Infectious diseases and pathogenesis

  • Alternative RNA splicing

  • RNA structure and molecular dynamics

  • Development and delivery of RNA therapeutics

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Government Institutes & Academic Centers

  • Pharmaceutical & Biotechnology Companies

  • Contract research Organizations (CROs)

  • Hospitals & Clinics

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait